We engineer inhibitors of protein-protein interactions starting from natural binding partners as well as from unrelated small protein domains.Such inhibitors could be evolved to selectively target only one family member among hundreds of homologs, making them attractive drug candidates. Our approaches could be applied to design the therapeutics for any disease where a known protein-protein interaction plays a crucial role.